November 2023 Vol 16, No 6
This section provides a brief overview of new cancer drugs and new indications approved by the FDA between September 11, 2023, and October 16, 2023. Read More ›
Improving clinical outcomes in the second line of treatment in patients with advanced biliary tract cancer remains an important goal, and researchers have been exploring various therapeutic targets, including HER2, an oncogene that creates a protein that encourages cell growth and accelerates the spread of cancers. Read More ›
By Nadia Jaber
It was once thought that after guiding the development of male sex organs in a fetus, the Y chromosome did not do much else. But over the past few years, results from multiple studies have challenged that belief. The most recent evidence comes from a new study that suggests that the Y chromosome may actually protect men from aggressive bladder cancer. Read More ›
Washington, DC—On September 6, 2023, the Association for Accessible Medicines, the leading trade association for generic and biosimilar manufacturers, released its 2023 U.S. Generic & Biosimilar Medicines Savings Report highlighting the value of generic and biosimilar medicines. Read More ›
Philadelphia, PA—Patients with pancreatic cancer who took the benzodiazepine lorazepam (Ativan), commonly prescribed to treat anxiety during cancer treatment, had a shorter progression-free survival than patients who did not, according to results published in Clinical Cancer Research, a journal of the American Association for Cancer Research. Read More ›
Chicago, IL—It is well documented that clinical trials thus far have for the most part excluded underserved populations, and that means the results of these trials cannot be generalized to society at large. Fortunately, the federal government and medical societies have taken aim at remedying this imbalance in accrual for clinical trials. Read More ›
The American Society of Clinical Oncology has issued an update to its guidelines for the practical assessment and management of vulnerabilities in patients aged ≥65 years receiving systemic cancer treatment. Read More ›